Latest News
Mirecule expands collaboration with Sanofi to advance FSHD therapy
18 March 2026 - Mirecule Inc, a developer of Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, on Wednesday announced an expansion of its strategic collaboration with French healthcare company Sanofi S.A. (Euronext Pari...
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
18 March 2026 - South Korean biopharmaceutical company Samsung Bioepis Co Ltd on Wednesday announced a global development and commercialisation agreement with Sandoz Group AG (SIX:SDZ), a generics and biosimilars company based in Switzerland.The agre...
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, an investigational oral glucosyl...
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
18 March 2026 - Alebund Pharmaceuticals, a China-based, renal-focused biopharmaceutical company, announced on Tuesday that it has signed licensing and equity agreements with R1 Therapeutics Inc, a newly launched clinical-stage biotechnology company.R...
Frost & Sullivan names Abzena a market-leading ADC CDMO
18 March 2026 - Abzena, an end-to-end integrated contract development and manufacturing organisation (CDMO) for complex biologics and bioconjugates, announced on Tuesday it has been named a leader in the Frost Radar Report for Antibody-Drug Conjugate...